RTTNews BiotechDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 19:26:53·⟳ 抓取 19:30:24 +3m31s·⚡ 决策 10-15 19:33:39 +3m15s·12.0 天前
安徕生物泰诺亚与礼来、默克(德国)达成AN4035联用西妥昔单抗临床试验供药合作
这是一项无首付款、无里程碑、无股权或分成的I期试验免费供药安排，仅具轻度背书意义，不改变ANL基本面或近期价值；而ANL正处于急跌通道、流动性极差，盘前对该消息反应为冲高回落且仍为负收益，软催化叠加强下行趋势，做多缺乏正期望，做空又无由本事件构成的负面催化，故回避。
📄 原文RTTNews Biotech↗ 原文
Adlai To Enter Clinical Trial Collaborations With Lilly, Merck KGaA To Explore Cetuximab With AN4035
Adlai Nortye Group (ANL) announced clinical trial collaboration and supply agreements with Eli Lilly and Company (LLY)…
不做 Adlai Nortye Group / 安徕生物泰诺亚（ANL.US）
本条仅为I期试验的免费供药合作、无首付款/里程碑/股权等任何经济条款，也无临床数据，催化强度不足以形成短线edge；而股价处急跌通道(5日-22.6%、20日-29.9%)、日均成交额仅约350万美元、盘前借消息冲高13.31后回落至10.67仍为负收益，风险收益差。礼来与默克(德国)作为超大盘供药方不受影响，亦无可交易的二阶标的，故整条事件回避。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
礼来与默克(德国)免费供西妥昔单抗支持AN4035的I期试验，属轻度外部背书但无经济条款、无数据；ANL近5日跌22.6%、20日跌29.9%且盘前冲高回落，软利好难逆急跌趋势，风险收益不足，不做。
消息传播链
- 公司官方通稿首发与礼来、默克(德国)的临床试验供药合作，无任何金额条款市场反应:盘前价格一度冲高至13.31后回落至10.67，相对前收10.88约-1.9%
- 信号源转载公司通稿，无新增事实
关键理由
- 合作仅为两家大药厂免费供应已上市的西妥昔单抗用于I期试验，公告无任何付款、里程碑或权益条款，对约7亿美元市值公司无量化业绩增量
- AN4035仍在I期早期、无数据读出，本条消息不构成需求或价值验证的强催化
主要风险
- ANL近5日-22.6%、10/13单日-17.3%、10/14再跌7.4%，处于明确急跌通道，下跌触发因素尚未从一手源排除，逆势左侧做多风险高
- 流动性极差(20日日均成交额约354万美元、盘前仅约2千股)，盘前一度冲高至13.31再回落至10.67，显示借消息派发、滑点与假突破风险大
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-14 · 影响 weakens
近5日-22.6%、20日-29.9%，媒体报道股价‘plunges 26%’，下跌触发因素未经一手源排除，构成强逆势逆风
检索:Adlai Nortye ANL stock drop October 2026 offering / clinical setback 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例空白加上软催化、急跌趋势与差流动性，共同支持回避而非试探性做多
方向:无可用于校准的高相似首发先例；‘大药厂免费供药支持小型biotech早期试验’这一机制本身通常仅带来温和、短暂的情绪反应，不构成方向性胜率证据
涨幅量级:样本不足，无法用对齐先例校准幅度
形态:本轮盘前冲高回落与软利好常见的借消息派发形态一致，但缺乏可回测先例支撑量化结论
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`adlai nortye an4035 cetuximab lilly merck kgaa clinical trial collaboration | adlai nortye anl an4035 pan-ras adc phase i supply agreement | 安徕生物泰诺亚 an4035 西妥昔单抗 礼来 默克 合作`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达 - stock_quote 成功 stock_tools HTTP · 2,629 ms
{ - web_search 成功 doubao_search · 1,630 ms
豆包搜索结果（原始查询:Adlai Nortye AN4035 cetuximab Eli Lilly Merck KGaA collaboration press release；API SearchType:web） - web_search 成功 doubao_search · 1,600 ms
豆包搜索结果（原始查询:Adlai Nortye ANL stock drop October 2026 news offering data；API SearchType:web）
原文全文
展开原文 · 1,158 字
Adlai Nortye Group (ANL) announced clinical trial collaboration and supply agreements with Eli Lilly and Company (LLY) and Merck KGaA (MRCG.DE,MRK.DE) for the anti-EGFR antibody cetuximab. The agreements will support Adlai Nortye's ongoing Phase I trial evaluating AN4035, a pan-RAS inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid tumors. Lilly will supply cetuximab at no cost for the U.S. clinical trial sites. Merck KGaA will supply cetuximab at no cost for the Australia and China clinical trial sites.
At last close on NasdaqGM, Adlai Nortye shares were trading at $10.88.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
At last close on NasdaqGM, Adlai Nortye shares were trading at $10.88.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
8d4792d46c· 2026-10-15 19:33 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前